Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
11 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 11
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇨🇳 ChinaCN-S01 · National Healthcare Security Administration / Ministry of Human Resources and Social Security · Notice on the 2025 National Reimbursement Drug ListOfficialPayment standards, same-generic-name and VBP linkage, transition arrangements and local implementation2025-12-07 / 2026-01-01Latest observed: 2025-12-07🇨🇳 ChinaCN-S02 · National Healthcare Security Administration · Official documents for the 2026 National Reimbursement Drug List adjustment work planOfficialFormal application, renewal and price-bidding rules2026-05-31Latest observed: 2026-05-31🇨🇳 ChinaCN-S03 · National Healthcare Security Administration · Policy interpretation of the 2026 National Reimbursement Drug List adjustment planOfficialTwo-year agreements, the eight-year threshold, renewal and price-bidding changes2026-05-09Latest observed: 2026-05-09🇨🇳 ChinaCN-S04 · National Healthcare Security Administration / National Health Commission · Guiding opinion on the dual-channel management mechanism for negotiated medicinesOfficialDual-channel definition, supply requirements and medical-insurance payment2021-05-10Latest observed: 2021-05-10🇨🇳 ChinaCN-S05 · General Office of the State Council / republished by the National Healthcare Security Administration · Several Opinions on Improving the Drug Price Formation Mechanism (State Council General Office Document [2026] No. 9)OfficialVBP, provincial listing, payment standards, retail, RWE and price governanceIssued 30 Mar 2026; published 14 Apr 2026Latest observed: 2026-04-14🇨🇳 ChinaCN-S06 · National Healthcare Security Administration · Interim Measures for the Administration of Medicines under Basic Medical InsuranceOfficialFoundation for expert review, negotiation, renewal and payment compliance2020-07-31 / 2020-09-01Latest observed: 2020-07-31🇨🇳 ChinaCN-S07 · General Office of the State Council · Opinion on Normalizing and Institutionalizing Centralized Volume-Based Procurement of MedicinesOfficialNational institutional foundation for VBP2021-01-28Latest observed: 2021-01-28🇨🇳 ChinaCN-S08 · National Healthcare Security Administration · Announcement of the National Centralized Drug Procurement Document (GY-YD2025-1)OfficialEntry point for the latest procurement round, participating entities and committed demand2025-09-20Latest observed: 2025-09-20🇨🇳 ChinaCN-S09 · National Medical Products Administration · NMPA Announcement No. 50 of 2026: Good Clinical Practice (2026 Revision)OfficialClinical-evidence quality, participant protection, proportionate risk management, data reliability and traceability, and sponsor/investigator dutiesAnnounced 21 May 2026; published 8 Jun 2026; effective 1 Sep 2026Latest observed: 2026-06-08🇨🇳 ChinaCN-S10 · National Healthcare Security Administration · Questions and answers on the first batch of 2026 medical-insurance payment scopesOfficialImplementation of payment scope and interpretation of clinical scenarios2026-04-17Latest observed: 2026-04-17🇨🇳 ChinaCN-S11 · National Healthcare Security Administration Guidance Center · Draft Guidelines for Comprehensive Real-World Medical-Insurance Value Assessment of Medicines (Trial) for public commentOfficialPolicy status of RWE and boundaries against overstatement2026-01-14Latest observed: 2026-01-14For education only — not regulatory, pricing or legal advice.